Showing 2881-2890 of 3315 results for "".
- ViGeneron and WuXi Advanced Therapies Enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapyhttps://modernod.com/news/vigeneron-and-wuxi-advanced-therapies-enter-strategic-manufacturing-partnership-for-next-generation-ophthalmic-gene-therapy/2478606/ViGeneron and WuXi Advanced Therapies announced a partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program. ViGeneron’s gene therapy pipeline addresses ophthalmic diseases with high unmet medical needs. Its lead pro
- New Survey Finds Critical Need for Education on Cataracts and Modern Treatment Optionshttps://modernod.com/news/new-survey-finds-critical-need-for-education-on-cataracts-and-modern-treatment-options/2478601/Johnson & Johnson Vision announced findings from a new survey that assessed awareness of cataracts among adults around the world. Cataracts are the leading cause of blindness globally,[1] with more than 90% of people developing cataracts by age
- Vitamin Sciences Lauches Visivite Blue Light Basher Ocular Supplementhttps://modernod.com/news/vitamin-sciences-lauches-visivite-blue-light-basher-ocular-supplement/2478604/Vitamin Science has added to its arsenal of quality ocular supplements with its launch of VisiVite Blue Light Basher earlier this year. High energy blue light is everywhere—cell phones, TV’s, LED lights and sunlight itself. To
- Eluminex Biosciences Announces Closing of $50 Million Series A Financinghttps://modernod.com/news/eluminex-biosciences-announces-closing-of-50-million-series-a-financing/2478597/China-based Eluminex Biosciences announced the completion of a $50 million Series A Financing, which will be used to develop a pipeline addressing critical unmet medical needs in vision-threatening diseases for patients. The financing was co-led by Lilly Asia
- Moderna’s mRNA COVID-19 Vaccine 94.1% Effective at Final Analysishttps://modernod.com/news/modernas-mrna-covid-19-vaccine-94-1-effective-at-final-analysis/2478596/Moderna announced Monday that the primary efficacy analysis of the phase 3 COVE study showed that its experimental mRNA-based COVID-19 vaccine mRNA-1273 had an efficacy rate of 94.1%, confirming the level observed at the first interim analysis. The company noted that the latest data were based on
- CORE and Myopia Profile Form Alliance to Expand Clinical Research and Professional Education Capabilitieshttps://modernod.com/news/core-and-myopia-profile-form-alliance-to-expand-clinical-research-and-professional-education-capabilities/2478595/The Centre for Ocular Research & Education (CORE) and Myopia Profile announced an alliance designed to expand both organizations’ services and reach. The affiliation aims to grow CORE’s extensive clinical research capabilities, adding expertise in specialty lenses, gas permeable, orthokerato
- Despite Impressive Data, FDA’s Coronavirus Vaccine Reviews Will Take Weeks, Not Days, Official Sayshttps://modernod.com/news/despite-impressive-data-fdas-coronavirus-vaccine-reviews-will-take-weeks-not-days-official-says/2478574/As leading COVID-19 vaccines post positive phase 3 data and near FDA submissions, the agency official in charge of reviewing vaccines is emphasizing transparency and patience during the high-stakes process, according to a FiercePharma
- Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelineshttps://modernod.com/news/hydrus-microstent-receives-highest-designation-of-any-migs-device-as-part-of-aao-treatment-guidelines/2478570/Ivantis, developer of the novel Hydrus Microstent MIGS device, announced that the American Academy of Ophthalmology (AAO) has designated the Hydrus Microstent as “Level 1, Moderate Quality, Strong Recommendation.” The designation is the highest of any MIGS device in its 2020 Preferred Practice Pa
- Kala Pharmaceuticals Provides Update on Launch Plans for Eysuvis for the Treatment of Dry Eye Diseasehttps://modernod.com/news/kala-pharmaceuticals-provides-update-on-launch-plans-for-eysuvis-for-the-treatment-of-dry-eye-disease/2478550/Kala Pharmaceuticals provided an update on its plans to launch Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease. “We continue to make significant progress on our plans to launch Eysuvis and
- Rural Hospitals Struggle to Find Places to Transfer Patients Amid COVID-19 Surgeshttps://modernod.com/news/rural-hospitals-struggle-to-find-places-to-transfer-patients-amid-covid-19-surges/2478551/Norton County Hospital is facing a major problem in recent days: Figuring out where to send patients that need a higher level of care. As larger hospitals become overwhelmed with serious cases of COVID-19, the options are dwindling. For Norton, the closest hospital that it has been able to